AvantGuard Raised $2.85M to Accelerate Research and Development

The funding will be utilized to accelerate the development and expansion of AvantGuard's innovative antimicrobial chemistries.


AvantGuard, a fast-growing company in the antimicrobial industry, has successfully completed its seed funding round, raising $2.85 million. The funding will be utilized to accelerate the development and expansion of AvantGuard’s innovative antimicrobial chemistries. Additionally, the company plans to hire additional scientists to further enhance their product and expand their global presence.

The seed round attracted new investments from Blue Ledge Capital, along with follow-on investments from prominent investors including SOSV, LaunchNY, and Red Bear Angels. These investors recognize the potential of AvantGuard’s cutting-edge technology, which offers unique solutions for managing surfaces and providing long-term protection against viruses, bacteria, fungi, and mold. AvantGuard’s innovative approach has already gained recognition within the industry, and with the completion of the seed funding round, the company is well-positioned to make significant advancements in pathogen-fighting solutions worldwide.

Andy Roche, Founder of Blue Ledge Capital, expressed confidence in AvantGuard’s mission and innovative solutions. He emphasized the company’s unique approach to antimicrobial chemistries and their potential to revolutionize the industry. Blue Ledge Capital looks forward to partnering with AvantGuard as they continue to develop their technology and expand their global reach, particularly in sectors such as hospitals, food production, cruise ships, and lodging.

With the additional funding, AvantGuard plans to expand its research and development efforts, recruit more scientists, and further enhance its product offerings. The company aims to revolutionize the antimicrobial industry by providing innovative solutions that ensure continuous protection against dangerous pathogens, contributing to a healthier and safer world. Combined with over $7.5 million in grants funding, the new funds will empower AvantGuard to drive advancements in antimicrobial technologies and strengthen its market presence.

Ted Eveleth, CEO of AvantGuard, expressed excitement about securing significant investment and the opportunity to bring their innovative chemistries to market at an accelerated pace. He highlighted the company’s team of world-class scientists who are dedicated to addressing major challenges in the antimicrobial industry. Eveleth expressed gratitude for the support and trust placed in AvantGuard by their investors, all of whom share the company’s vision and recognize its expertise in the field.

With the successful completion of the seed funding round, AvantGuard is poised to make significant strides in antimicrobial technology, contributing to the development of effective and long-lasting solutions for pathogen control and promoting a safer and healthier world.

Related Stories

Latest News Stories